AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29874199 — intervention group
Group type: EXPERIMENTAL
Intervention: LactoWise® (4.5 billion live cells of bacillus coagulans and galactomannans, 300 mg)
Number of subjects: 60
Study 29874199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg of calcium citrate yielding 126 mg of elemental calcium)
Number of subjects: 60
Study 29874199 — intervention group
Group type: EXPERIMENTAL
Intervention: LactoWise®
Number of subjects: 60
Study 29874199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31864217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based minimal-contact CBT (guided Internet-delivered CBT, unguided Internet-delivered CBT, bibliotherapy)
Number of subjects: 132
Study 31864217 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based minimal-contact CBT
Number of subjects: 132
Study 31864217 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 132
Study 30428750 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice (the patient could choose the gender of the practitioner)
Number of subjects: 1060
Study 30428750 — intervention group
Group type: EXPERIMENTAL
Intervention: Same gender (female practitioner by default)
Number of subjects: 1060
Study 30428750 — intervention group
Group type: COMPARATOR
Intervention: Control (practitioner's gender is unknown)
Number of subjects: 1060
Study 30428750 — intervention group
Group type: EXPERIMENTAL
Intervention: Opposite gender (male practitioner by default)
Number of subjects: 1060
Study 28894361 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 IU vitamin D3 per day
Number of subjects: 50
Study 28894361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25761469 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study 23500237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (target dose 1000 mg bid)
Number of subjects: 949
Study 23500237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 22340311 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS, transforaminal lumbar interbody fusion via MAST Quadrant retractor)
Number of subjects: 79
Study 22340311 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (improved transforaminal lumbar interbody fusion)
Number of subjects: 79
Study 22340311 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 79
Study 22340311 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 79
Study 19699156 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV XR (1000mg/day)
Number of subjects: 555
Study 17461854 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r (600/100 mg bid)
Number of subjects: 1360
Study 17461854 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r (500/200 mg bid)
Number of subjects: 1360
Study 17461854 — intervention group
Group type: COMPARATOR
Intervention: CPI (Control)
Number of subjects: 1360
Study 17461854 — intervention group
Group type: COMPARATOR
Intervention: TMC114/r vs CPI
Number of subjects: 1360
Study 17461854 — intervention group
Group type: COMPARATOR
Intervention: TPV/r vs CPI
Number of subjects: 1360
Study 17461854 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC114/r
Number of subjects: 1360
Study 15351193 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (B-14, n=1439)
Number of subjects: 3682
Study 15351193 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFT (Cyclophosphamide, Methotrexate, Fluorouracil, and Tamoxifen) (B-20, n=789)
Number of subjects: 3682
Study 15351193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (B-14, n=1453)
Number of subjects: 3682
Study 15351193 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (B-20, n=788)
Number of subjects: 3682
Study 12089852 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic, hormonal, and surgical treatment
Number of subjects: 0
Study 12089852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory awareness-directed physiotherapy
Number of subjects: 0
Study 12089852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural stress management intervention
Number of subjects: 0
Study 12089852 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible biopsychosocial approach
Number of subjects: 0
Study 12089852 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic medical evaluation and follow-up
Number of subjects: 0
Study 9642607 — intervention group
Group type: COMPARATOR
Intervention: gemeprost 1 mg 3 hourly for 5 doses
Number of subjects: 100
Study 9642607 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol 200 mcg 6 hourly for 4 doses
Number of subjects: 100
Study 9642607 — intervention group
Group type: COMPARATOR
Intervention: gemeprost
Number of subjects: 100
Study 9642607 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol
Number of subjects: 100
Study 7661175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone, 1 g, b.i.d.
Number of subjects: 52
Study 7661175 — intervention group
Group type: COMPARATOR
Intervention: Naproxen, 500 mg, b.i.d.
Number of subjects: 52
Study 2504171 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human gamma-interferon (rHu gamma-IFN)
Number of subjects: 105
Study 2504171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 905127 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 20 microgram/kg/day (loading dose of 20 microgram/kg followed by maintenance dose of 7 microgram/kg every 8 hours)
Number of subjects: 0
Study 905127 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin levels exceeding 5 ng/ml
Number of subjects: 0
Study 31358093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal irrigation
Number of subjects: 87
Study 31358093 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal irrigation (placebo)
Number of subjects: 87
Study 31358093 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IgE levels preoperatively
Number of subjects: 87
Study 31358093 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of pre and postoperative serum IgE levels
Number of subjects: 87
Study 28712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional assessment and management
Number of subjects: 1742
Study 28712113 — intervention group
Group type: COMPARATOR
Intervention: Receiving tuberculosis treatment
Number of subjects: 1742
Study 28712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index, mid-upper arm circumference, haemoglobin, systolic blood pressure
Number of subjects: 1742
Study 28712113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index in men
Number of subjects: 1742
Study 28712113 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein and CD4 count
Number of subjects: 1742
Study 26158605 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (60 mg applied to the axillae for 16 weeks)
Number of subjects: 76
Study 26158605 — intervention group
Group type: COMPARATOR
Intervention: Placebo (applied to the axillae for 16 weeks)
Number of subjects: 76
Study 23006335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor adaptation training with a rotating visual scene
Number of subjects: 16
Study 23006335 — intervention group
Group type: COMPARATOR
Intervention: Control group with static scene
Number of subjects: 16
Study 22067312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose (AD) of mycophenolate mofetil (MMF) using therapeutic drug monitoring (TDM)
Number of subjects: 247
Study 22067312 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose (FD) regimen of mycophenolate mofetil (MMF)
Number of subjects: 247
Study 19421770 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal (5,000 U/5 mL)
Number of subjects: 155
Study 19421770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabotamp (oxidized regenerated cellulose patch, 2.5 x 5 cm)
Number of subjects: 155
Study 19421770 — intervention group
Group type: COMPARATOR
Intervention: Surgical procedures only
Number of subjects: 155
Study 17054603 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testing strips for 6 months
Number of subjects: 262
Study 17054603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no free testing strips)
Number of subjects: 262
Study 15283801 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (5 mg/kg/day, continuous regimen, either as capsule or oral suspension)
Number of subjects: 163
Study 10791448 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge to hospital-at-home (n = 93)
Number of subjects: 133
Study 10791448 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care and discharge (n = 40)
Number of subjects: 133
Study 8791962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 30
Study 8791962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1958942 — intervention group
Group type: EXPERIMENTAL
Intervention: Three treatment regimes (behavioural approach to diet and weight gain coupled with individual and family psychotherapy)
Number of subjects: 90
Study 1958942 — intervention group
Group type: EXPERIMENTAL
Intervention: Three treatment regimes
Number of subjects: 90
Study 1958942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study 7053265 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP (cyclophosphamide 400 mg/m2/day orally X 5, teniposide 100 mg/m2 iv X 1, prednisolone 60 mg/m2/day orally X 5)
Number of subjects: 164
Study 7053265 — intervention group
Group type: COMPARATOR
Intervention: COP (vincristine 1.4 mg/m2 iv X 1; maximum, 2 mg, with the same cyclophosphamide and prednisolone doses)
Number of subjects: 164
Study 7053265 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP
Number of subjects: 164
Study 7053265 — intervention group
Group type: COMPARATOR
Intervention: COP
Number of subjects: 164
Study 31733459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 31733459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31192716 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMASH-E intervention
Number of subjects: 58
Study 31192716 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 58
Study 28683300 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide
Number of subjects: 3132
Study 28683300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3132
Study 28683300 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 3132
Study 28683300 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 3132
Study 28683300 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 3132
Study 28683300 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 3132
Study 25342246 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 90
Study 25342246 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (normothermic)
Number of subjects: 90
Study 25072757 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Severe Sepsis Protocol (up to 4 L of IV fluids within 6 hours, guided by jugular venous pressure assessment, and dopamine and/or blood transfusion in selected patients)
Number of subjects: 112
Study 25072757 — intervention group
Group type: COMPARATOR
Intervention: Control group (managed as usual care)
Number of subjects: 112
Study 25072757 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Severe Sepsis Protocol
Number of subjects: 112
Study 25072757 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study 22103452 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 12
Study 22103452 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane
Number of subjects: 12
Study 22103452 — intervention group
Group type: EXPERIMENTAL
Intervention: desflurane
Number of subjects: 12
Study 20574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty (group CRYO; 24 patients with 31 lesions)
Number of subjects: 50
Study 20574796 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (group COBA; 26 patients with 34 lesions)
Number of subjects: 50
Study 20574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoplasty (group CRYO)
Number of subjects: 50
Study 20574796 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (group COBA)
Number of subjects: 50
Study 18047458 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes daily stretch of the wrist and finger flexors five days a week for four weeks
Number of subjects: 40
Study 18047458 — intervention group
Group type: COMPARATOR
Intervention: Routine upper-limb retraining five days a week
Number of subjects: 40
Study 16032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 60
Study 16032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal analgesia
Number of subjects: 60
Study 16032447 — intervention group
Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 60
Study 16032447 — intervention group
Group type: COMPARATOR
Intervention: Control/Flumazenil
Number of subjects: 60
Study 16032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal/Placebo
Number of subjects: 60
Study 16032447 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal/Flumazenil
Number of subjects: 60
Study 12086029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic (Capener) splints
Number of subjects: 24
Study 12086029 — intervention group
Group type: COMPARATOR
Intervention: Static (belly gutter) splints
Number of subjects: 24
Study 10420149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (50 mg once daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Number of subjects: 813
Study 10420149 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (250 mg three times daily) plus LHRHa (goserelin acetate 3.6 mg or leuprolide acetate 7.5 mg)
Number of subjects: 813
Study 7593526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg) plus sulprostone (250 micrograms)
Number of subjects: 381
Study 7593526 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 381
Study 2489853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Videodisc (IVD)
Number of subjects: 54
Study 2489853 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-Directed (TD)
Number of subjects: 54
Study 2489853 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed (SD)
Number of subjects: 54
Study 4583183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagotomy and pyloroplasty
Number of subjects: 100
Study 4583183 — intervention group
Group type: COMPARATOR
Intervention: Billroth I partial gastrectomy
Number of subjects: 100
Study 4583183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 31880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive adult education intervention (REAEI) delivered in 32 group therapeutic sessions over 16 weeks
Number of subjects: 320
Study 31880181 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 320
Study 29800331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 998
Study 29800331 — intervention group
Group type: EXPERIMENTAL
Intervention: Slim cigarette
Number of subjects: 998
Study 29800331 — intervention group
Group type: EXPERIMENTAL
Intervention: Pink cigarette
Number of subjects: 998
Study 29800331 — intervention group
Group type: COMPARATOR
Intervention: Plain gray cigarette
Number of subjects: 998
Study 28478791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM)
Number of subjects: 104
Study 28478791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 26598451 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance (SR) stimulation
Number of subjects: 36
Study 26598451 — intervention group
Group type: COMPARATOR
Intervention: No SR stimulation (control)
Number of subjects: 36
Study 23124914 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sialogogue spray containing 1% malic acid
Number of subjects: 70
Study 23124914 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 70
Study 21706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Online social network (OSN) usage
Number of subjects: 3012
Study 21706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend requests from patients or their family members
Number of subjects: 3012
Study 21706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical acceptability of interacting with patients within OSNs
Number of subjects: 3012
Study 21706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessimism about OSNs improving patient-doctor communication
Number of subjects: 3012
Study 21706268 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about maintaining patient confidentiality
Number of subjects: 3012
Study 19218542 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐MPH‐ER 20 to 40 mg/d
Number of subjects: 170
Study 19218542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 21744967 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored, multicomponent intervention
Number of subjects: 841
Study 21744967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 841
Study 16052676 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IFN beta‐1a alone (Group 1)
Number of subjects: 102
Study 16052676 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IFN beta‐1a in combination with ribavirin (Group 2)
Number of subjects: 102
Study 12444323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) regimen 1 starting with 3 IR tablets (n = 15)
Number of subjects: 64
Study 12444323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) regimen 2 starting with 10 IR tablets (n = 16)
Number of subjects: 64
Study 12444323 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) regimen 3 starting with 30 IR tablets (n = 16)
Number of subjects: 64
Study 12444323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 64
Study 9635520 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) morphine tablets administered every 12 hours
Number of subjects: 0
Study 9635520 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) morphine
Number of subjects: 0
Study 8076658 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 8076658 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2499233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CHO diet (10% calories from CHO)
Number of subjects: 8
Study 2499233 — intervention group
Group type: COMPARATOR
Intervention: High CHO diet (70% calories from CHO)
Number of subjects: 8
Study 4185887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment with carbimazole
Number of subjects: 181
Study 4185887 — intervention group
Group type: COMPARATOR
Intervention: Radioactive iodine (131)I therapy
Number of subjects: 181
Study 11340104 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber meal containing white beans
Number of subjects: 0
Study 11340104 — intervention group
Group type: COMPARATOR
Intervention: Low fiber meal containing rice and dry milk
Number of subjects: 0
Study 30203440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 50 mg with adrenaline 100 μg (BA-group, n = 14)
Number of subjects: 30
Study 30203440 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine without adrenaline (B-group, n = 16)
Number of subjects: 30
Study 29446060 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam group (20 ml of bupivacaine hydrochloride 0.25% + midazolam 50 μg/kg in 2 ml saline 0.9%)
Number of subjects: 60
Study 29446060 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 ml of bupivacaine hydrochloride 0.25% + 2 ml saline)
Number of subjects: 60
Study 27455035 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM-positive delirium assessment using Confusion Assessment Method (CAM)
Number of subjects: 243
Study 27455035 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium severity measured with Memorial Delirium Assessment Scale (MDAS)
Number of subjects: 243
Study 27455035 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician identification of delirium
Number of subjects: 243
Study 27455035 — intervention group
Group type: COMPARATOR
Intervention: Comparison of delirium frequency in patients aged 65 and older vs. younger than 65
Number of subjects: 243
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 m front-crawl style
Number of subjects: 46
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 m front-crawl style
Number of subjects: 46
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 m front-crawl style
Number of subjects: 46
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke length (SL) and stroke index (SI)
Number of subjects: 46
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stroke parameters
Number of subjects: 46
Study 24231272 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometrical variables (upper limbs and height)
Number of subjects: 46
Study 21732090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 13
Study 21732090 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri SD2112 and PTA 5289
Number of subjects: 13
Study 21732090 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 13
Study 20170698 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) combined with donepezil (7.5g, t.i.d.) for 4 weeks
Number of subjects: 61
Study 20170698 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) combined with donepezil
Number of subjects: 61
Study 20170698 — intervention group
Group type: COMPARATOR
Intervention: Non-Yokukansan (donepezil monotherapy)
Number of subjects: 61